Randomized, double-blind, placebo-controlled phase II study of carboplatin and paclitaxel with or without vorinostat, a histone deacetylase inhibitor (HDAC), for first-line therapy of advanced non-small cell lung cancer (NCI 7863)

被引：0
|
作者：
Ramalingam, S. S.
Maitland, M.
Frankel, P.
Argiris, A. E.
Koczywas, M.
Gitlitz, B.
Espinoza-Delgado, I.
Vokes, E. E.
Gandara, D. R.
Belani, C. P.
机构：
[1] Emory Univ, Atlanta, GA 30322 USA
[2] Univ Chicago, Chicago, IL 60637 USA
[3] City Hope Comprehens Canc Ctr, Duarte, CA USA
[4] Univ Pittsburgh, Pittsburgh, PA USA
[5] Univ So Calif, Los Angeles, CA USA
[6] NCI, Bethesda, MD 20892 USA
[7] Univ Calif Davis, Ctr Canc, Sacramento, CA 95817 USA
[8] Penn State Hershey Canc Inst, Hershey, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8004
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Randomized, double-blind, phase II study of carboplatin and paclitaxel with either vorinostat, a histone deacetylase inhibitor (HDAC), or placebo for first line therapy of advanced non-small cell lung cancer (NCI 7863)
    Ramalingam, Suresh S.
    Maitland, Michael
    Frankel, Paul
    Argiris, Athanassios
    Thomas, Sachdev
    Gitlitz, Barbara
    Koczywas, Marianna
    Espinoza-Delgado, Igor
    Vokes, Everett E.
    Gandara, David R.
    Belani, Chandra P.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S382 - S383
  • [2] Randomized, double-blind phase II/III study of first-line paclitaxel (P) plus carboplatin (C) in combination with vorinostat or placebo in patients with advanced non-small-cell lung cancer (NSCLC)
    Belani, C.
    Ramalingam, S.
    Kalemkerian, G.
    Mok, T.
    Rosell, R.
    Ahn, M. J.
    Sun, L.
    Gates, M.
    Lubiniecki, G. M.
    Govindan, R.
    EJC SUPPLEMENTS, 2009, 7 (02): : 507 - 507
  • [3] A comparative randomized, placebo-controlled, double-blind phase II study with and without enzastaurin in combination with paclitaxel and carboplatin as first-line treatment for advanced ovarian cancer.
    Vergote, I. B.
    Harter, P.
    Kovalenko, N.
    Bauknecht, T.
    Mansouri, K.
    Zhang, Y.
    Sehouli, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non-Small-Cell Lung Cancer
    Ramalingam, Suresh S.
    Maitland, Michael L.
    Frankel, Paul
    Argiris, Athanassios E.
    Koczywas, Marianna
    Gitlitz, Barbara
    Thomas, Sachdev
    Espinoza-Delgado, Igor
    Vokes, Everett E.
    Gandara, David R.
    Belani, Chandra P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (01) : 56 - 62
  • [5] A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Oral Talactoferrin in Combination with Carboplatin and Paclitaxel in Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer
    Digumarti, Raghunadharao
    Wang, Yenyun
    Raman, Ganapathi
    Doval, Dinesh C.
    Advani, Suresh H.
    Julka, Pramod K.
    Parikh, Purvish M.
    Patil, Shekhar
    Nag, Shona
    Madhavan, Jayaprakash
    Bapna, Ajay
    Ranade, Annantbhushan A.
    Varadhachary, Atul
    Malik, Rajesh
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : 1098 - 1103
  • [6] Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non-Small Cell Lung Cancer
    Ramalingam, Suresh S.
    Blais, Normand
    Mazieres, Julien
    Reck, Martin
    Jones, C. Michael
    Juhasz, Erzsebet
    Urban, Laszlo
    Orlov, Sergey
    Barlesi, Fabrice
    Kio, Ebenezer
    Keiholz, Ulrich
    Qin, Qin
    Qian, Jiang
    Nickner, Caroline
    Dziubinski, Juliann
    Xiong, Hao
    Ansell, Peter
    McKee, Mark
    Giranda, Vincent
    Gorbunova, Vera
    CLINICAL CANCER RESEARCH, 2017, 23 (08) : 1937 - 1944
  • [7] A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Paclitaxel-Carboplatin Alone or with Endostar for Advanced Non-small Cell Lung Cancer
    Han, Baohui
    Xiu, Qingyu
    Wang, Huimin
    Shen, Jie
    Gu, Aiqin
    Luo, Yi
    Bai, Chunxue
    Guo, Shuliang
    Liu, Wenchao
    Zhuang, Zhixiang
    Zhang, Yang
    Zhao, Yizhuo
    Jiang, Liyan
    Zhou, Jianying
    Jin, Xianqiao
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : 1104 - 1109
  • [8] BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer
    Zhou, Caicun
    Wu, Yi-Long
    Chen, Gongyan
    Liu, Xiaoqing
    Zhu, Yunzhong
    Lu, Shun
    Feng, Jifeng
    He, Jianxing
    Han, Baohui
    Wang, Jie
    Jiang, Guoliang
    Hu, Chunhong
    Zhang, Hao
    Cheng, Gang
    Song, Xiangqun
    Lu, You
    Pan, Hongming
    Zheng, Wenjuan
    Yin, Anny-Yue
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (19) : 2197 - U108
  • [9] A double-blind, randomized phase II study of dicycloplatin plus paclitaxel versus carboplatin plus paclitaxel as first-line therapy for patients with advanced non-small-cell lung cancers
    Liu, Ke-Jun
    Guan, Zhong-Zhen
    Liang, Ying
    Yang, Xu-Qing
    Peng, Jin
    Huang, He
    Shao, Qing-Xiang
    Wang, Meng-Zhao
    Zhu, Yun-Zhong
    Wu, Chang-Ping
    Wang, Shao-Bin
    Xiong, Jian-Ping
    Bai, Yu-Xian
    Yu, Shi-Ying
    Zhang, Yang
    Hu, Xiao-Hua
    Feng, Ji-Feng
    Wu, Shi-Xiu
    Jiao, Shun-Chang
    Zhou, Cai-Cun
    Wang, Jie
    Wu, Hai-Ying
    ARCHIVES OF MEDICAL SCIENCE, 2014, 10 (04) : 717 - 724
  • [10] BIWEEKLY CARBOPLATIN AND PACLITAXEL AS FIRST-LINE THERAPY FOR ELDERLY ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS (PHASE II STUDY)
    Kota, I.
    Soejima, K.
    Naoki, K.
    Yasuda, H.
    Terai, H.
    Daisuke, A.
    Ohgino, K.
    Yoda, S.
    Ikemura, S.
    Betsuyaku, T.
    ANNALS OF ONCOLOGY, 2012, 23 : 422 - 422
12345